A Phase 1 interventional study of Dabigatran etexilate and Dabigatran etexilate in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-05-19.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this Phase I trial is to demonstrate the bioequivalence of two capsules of dabigatran etexilate made from two different drug product batches.
The reference batch is dabigatran etexilate hard capsules 150 mg using the currently approved capsule shell (Qualicaps). The test batch is dabigatran etexilate 150 mg hard capsules using a new capsule shell (Capsugel). The test batch is the drug product intended for future commercial use.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Capsugel (T), oral administration
Drug: Dabigatran etexilate
Qualicaps (R), oral administration
Drug: Dabigatran etexilate
150 mg Capsugel (T)
150 mg Qualicaps (R)
Area Under the Curve 0 to tz (AUC0-tz) of Total Dabigatran
Area under the concentration-time curve of total dabigatran in plasma from time 0 to the time of the last quantifiable data point, adjusted for treatment, period and sequence (all fixed effects), and random subject effect.
Time frame: 60 hours
Maximum Measured Concentration (Cmax) of Total Dabigatran in Plasma
Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.
Time frame: 60 hours
Area Under the Curve 0 to Infinity (AUC0-∞) of Total Dabigatran.
Area under the concentration-time curve of total dabigatran in plasma over the time interval from 0 extrapolated to infinity. Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.
Time frame: 60 hours
AUC0-tz of Free Dabigatran.
Area under the concentration-time curve of free dabigatran in plasma from time 0 to the time of the last quantifiable data point. Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.
Time frame: 60 hours
Cmax of Free Dabigatran in Plasma.
Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.
Time frame: 60 hours
AUC0-∞ of Free Dabigatran.
Area under the concentration-time curve of free dabigatran in plasma over the time interval from 0 extrapolated to infinity. Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.
Time frame: 60 hours
| Milestone | Sequence: Qualicaps - Capsugel - Qualicaps - Capsugel | Sequence: Capsugel - Qualicaps - Capsugel - Qualicaps |
|---|---|---|
| Started | 90 | 90 |
| Completed | 88 | 88 |
| Not completed | 2 | 2 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Other | 0 | 1 |
Area under the concentration-time curve of total dabigatran in plasma from time 0 to the time of the last quantifiable data point, adjusted for treatment, period and sequence (all fixed effects), and random subject effect.
| ng*hr/mL | Capsugel | Qualicaps |
|---|---|---|
| Area Under the Curve 0 to tz (AUC0-tz) of Total Dabigatran | 1147.64 ± 32.32 | 908.48 ± 49.83 |
Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.
| ng/mL | Capsugel | Qualicaps |
|---|---|---|
| Maximum Measured Concentration (Cmax) of Total Dabigatran in Plasma | 134.44 ± 31.10 | 107.13 ± 49.67 |
Area under the concentration-time curve of total dabigatran in plasma over the time interval from 0 extrapolated to infinity. Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.
| ng*hr/mL | Capsugel | Qualicaps |
|---|---|---|
| Area Under the Curve 0 to Infinity (AUC0-∞) of Total Dabigatran. | 1175.05 ± 30.81 | 941.99 ± 46.53 |
Area under the concentration-time curve of free dabigatran in plasma from time 0 to the time of the last quantifiable data point. Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.
| ng*hr/mL | Capsugel | Qualicaps |
|---|---|---|
| AUC0-tz of Free Dabigatran. | 856.31 ± 33.15 | 678.43 ± 50.85 |
Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.
| ng/mL | Capsugel | Qualicaps |
|---|---|---|
| Cmax of Free Dabigatran in Plasma. | 106.66 ± 31.34 | 85.12 ± 50.33 |
Area under the concentration-time curve of free dabigatran in plasma over the time interval from 0 extrapolated to infinity. Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.
| ng*hr/mL | Capsugel | Qualicaps |
|---|---|---|
| AUC0-∞ of Free Dabigatran. | 888.86 ± 31.20 | 714.01 ± 47.16 |
Collected over Approximately 7 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Qualicaps | — | 0/180 (0%) | 37/180 (20.6%) |
| Capsugel | — | 0/180 (0%) | 34/180 (18.9%) |
| Event | Qualicaps | Capsugel |
|---|---|---|
| HeadacheNervous system disorders | 37/180 | 34/180 |
Treated set includes all patients who received at least one study treatment.
| Age, Continuous(Years) | Sequence: Qualicaps - Capsugel - Qualicaps - Capsugel | Sequence: Capsugel - Qualicaps - Capsugel - Qualicaps | Total |
|---|---|---|---|
| Mean | 39.8 ± 10.1 | 39.4 ± 9.1 | 39.6 ± 9.6 |
| Sex: Female, Male(Participants) | Sequence: Qualicaps - Capsugel - Qualicaps - Capsugel | Sequence: Capsugel - Qualicaps - Capsugel - Qualicaps | Total |
|---|---|---|---|
| Female | 46 | 47 | 93 |
| Male | 44 | 43 | 87 |
The record gives a start of Jan 2011 and a primary completion of Apr 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2012, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dabigatran